메뉴 건너뛰기
Annals of the Rheumatic Diseases
Volumn 63, Issue 6, 2004, Pages 744-745
Successful treatment of genital ulcers with infliximab in Behçet's disease
Author keywords

[No Author keywords available]
Indexed keywords

AZATHIOPRINE; COLCHICINE; DEXAMETHASONE; INFLIXIMAB; PREDNISOLONE;
EID: 2442681859     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.010975     Document Type: Article
Times cited : (62)
References (8)
  • 1
    • 0035002354 scopus 로고    scopus 로고
    • Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy
    • Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001;60:637.
    • (2001) Ann Rheum Dis , vol.60 , pp. 637
    • Goossens, P.H.1    Verburg, R.J.2    Breedveld, F.C.3
  • 2
    • 0035042194 scopus 로고    scopus 로고
    • Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab
    • Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001;40:473-4.
    • (2001) Rheumatology (Oxford) , vol.40 , pp. 473-474
    • Robertson, L.P.1    Hickling, P.2
  • 3
    • 0036797056 scopus 로고    scopus 로고
    • Behçet's syndrome: Response to infliximab after failure of etanercept
    • Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002;41:1213-14.
    • (2002) Rheumatology (Oxford) , vol.41 , pp. 1213-1214
    • Estrach, C.1    Mpofu, S.2    Moots, R.J.3
  • 4
    • 0035126857 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report
    • Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology 2001;120:995-9.
    • (2001) Gastroenterology , vol.120 , pp. 995-999
    • Hassard, P.V.1    Binder, S.W.2    Nelson, V.3    Vasiliauskas, E.A.4
  • 5
    • 0034775499 scopus 로고    scopus 로고
    • Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody
    • Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001;49:725-8.
    • (2001) Gut , vol.49 , pp. 725-728
    • Travis, S.P.1    Czajkowski, M.2    McGovern, D.P.3    Watson, R.G.4    Bell, A.L.5
  • 7
    • 0346845231 scopus 로고    scopus 로고
    • Etanercept is beneficial in controlling the mucocutaneous lesions of Behçet's syndrome (BS) at short term but does not suppress the pathergy reaction and the cutaneous response to intradermally injected monosodium urate (MSU) crystals: A double blind placebo controlled trial
    • Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Yurdakul S, Hamuryudan V, et al. Etanercept is beneficial in controlling the mucocutaneous lesions of Behçet's syndrome (BS) at short term but does not suppress the pathergy reaction and the cutaneous response to intradermally injected monosodium urate (MSU) crystals: a double blind placebo controlled trial [abstract]. Arthritis Rheum 2002;46(suppl):S206.
    • (2002) Arthritis Rheum , vol.46 , Issue.SUPPL.
    • Melikoglu, M.1    Fresko, I.2    Mat, C.3    Ozyazgan, Y.4    Yurdakul, S.5    Hamuryudan, V.6
  • 8
    • 0036838908 scopus 로고    scopus 로고
    • Behçet's disease: A new target for anti-tumour necrosis factor treatment
    • Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dh 2002;61(suppl II):ii51-3.
    • (2002) Ann Rheum Dh , vol.61 , Issue.2 SUPPL.
    • Sfikakis, P.P.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.